U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Custom RX LLC dba Custom Rx Pharmacy and Wellness Concepts - 559540 - 01/20/2022
  1. Warning Letters

CLOSEOUT LETTER

Custom RX LLC dba Custom Rx Pharmacy and Wellness Concepts MARCS-CMS 559540 —

Delivery Method:
UPS Next Day
Product:
Drugs
Recipient:
Recipient Name
Jan R. Gerber
Recipient Title
Owner/President and CEO
Custom RX LLC dba Custom Rx Pharmacy and Wellness Concepts

3510 N Ridge Rd.
Suite 900
Wichita, KS 67205-1224
United States

Issuing Office:
Detroit District Office

United States

Dear Mr. Gerber:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (Case #559540), dated October 18, 2018). Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Nicholas F. Lyons
Director of Compliance Branch
Division of Pharmaceutical Quality Operations III

Back to Top